

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 1, 2011**

**ONCOGENEX PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other Jurisdiction of Incorporation)	<b>033-80623</b> (Commission File Number)	<b>95-4343413</b> (IRS Employer Identification No.)
<b>1522 217th Place S.E. Bothell, Washington</b> (Address of Principal Executive Offices)		<b>98021</b> (Zip Code)

Registrant's telephone number, including area code: **(425) 487-9500**

N/A  
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As previously announced, Michelle Burris was appointed Executive Vice President, Operations and Chief Financial Officer of the Company and designated as the Company's principal financial officer effective January 3, 2011. On January 1, 2011, the Board of Directors of the Company (the "Board") determined that Cameron Lawrence shall continue to serve as the Company's principal accounting officer and treasurer, and therefore, the prior designation of Michelle Burris to such position was never given effect.

On January 3, 2011, Michelle Burris resigned from the Board, effective immediately. In connection therewith, the Board fixed the size of the Board at six directors.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ONCOGENEX PHARMACEUTICALS, INC.**  
(Registrant)

Date: January 5, 2011

By: /s/ Cameron Lawrence  
Name: Cameron Lawrence  
Title: Principal Accounting Officer